How Efferon’s Blood‑Purification Technology Targets Sepsis and Septic Shock

In 2026, Efferon NEO received CE MDR certification in Europe, making it one of the first hemoadsorption devices approved for treating neonatal and pediatric sepsis patients under the EU’s Medical Device Regulation framework.

How the Hemoadsorption Technology Works

Efferon’s platform relies on a form of extracorporeal hemoperfusion. During treatment, a patient’s blood flows through a cartridge containing specialized adsorbent materials before being returned to the body.

Inside the cartridge are porous polymer beads made of surface‑modified hypercrosslinked polystyrene, engineered with chemical ligands that selectively bind bacterial endotoxins (lipopolysaccharides, or LPS).

The beads also adsorb other molecules associated with severe inflammation, including cytokines and damage‑associated molecular patterns. This creates a multimodal adsorption effect, targeting both the infection‑related toxin and the immune response it triggers.

The goal is to:

• reduce circulating endotoxin levels
• lower inflammatory mediator concentrations
• stabilize hemodynamics and organ function during septic shock

Because the therapy removes harmful molecules rather than delivering drugs, it is typically used in addition to antibiotics, supportive care, and other ICU treatments.

Evidence From Clinical Studies

Clinical studies have investigated whether endotoxin‑targeted hemoperfusion can improve outcomes in septic shock.

In a multicenter randomized clinical trial evaluating Efferon LPS hemoperfusion, patients receiving the treatment showed reductions in endotoxin activity and improvements in several clinical parameters, including vasopressor requirements and organ‑failure scores compared with standard therapy alone.

These findings support the concept that removing endotoxins and inflammatory mediators from circulation may help stabilize patients with severe systemic infection.

However, as with many extracorporeal therapies, researchers continue to study which patients benefit most and when the therapy should be initiated.

Potential Impact on ICU Treatment and Costs

According to company and distributor materials, hemoadsorption therapy may reduce ICU resource utilization by helping stabilize patients faster and potentially shortening time on mechanical ventilation or intensive care treatment.

Independent sources generally describe this benefit qualitatively rather than providing standardized estimates of ICU‑day reductions or cost savings. In practice, outcomes likely depend on patient severity, timing of therapy, and local ICU protocols.

Adoption and Global Use

Efferon reports that its devices have been used to treat more than 10,000 critically ill patients and are distributed through international partners across multiple regions.

The company has also expanded globally through partnerships, including regulatory approvals or distribution agreements in new markets such as Australia.

While adoption varies by country, extracorporeal blood‑purification approaches are increasingly explored in critical‑care medicine, particularly in settings where sepsis management remains challenging.

Recent Funding and Expansion Plans

In 2026, Efferon raised €2.5 million in a seed funding round led by private investors from the DACH region (Germany, Austria, and Switzerland).

The company says the funding will primarily support:

• commercial expansion of Efferon LPS across Europe
• further development of its hemoadsorption platform
• broader international deployment of its blood‑purification technologies

Why Sepsis Remains a Global Focus

Sepsis is widely recognized as a major global health problem. Estimates suggest 20–30 million cases occur worldwide each year, making it a leading cause of death and organ failure in intensive care units.

Because mortality remains high despite antibiotics and supportive care, researchers and device developers continue to explore complementary approaches—such as extracorporeal blood purification—to control the immune dysregulation that drives severe disease.

Efferon’s technology represents one example of this emerging class of therapies aimed at modulating the body’s inflammatory response rather than directly attacking the infection itself.

As research continues, the role of hemoadsorption in routine sepsis management will depend on further clinical evidence, regulatory adoption, and integration into critical‑care protocols.